FY2030 EPS Estimates for Biohaven Reduced by HC Wainwright

Biohaven Ltd. (NYSE:BHVN) – Research analysts at HC Wainwright reduced their FY2030 earnings per share estimates for Biohaven in a report released on Wednesday, August 12th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $1.84 per share for the year, down from their previous forecast of $2.12. HC Wainwright has a “Neutral” rating and a $10.00 price objective on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($3.11) per share.

Several other analysts have also weighed in on the stock. Bank of America reiterated an “underperform” rating and set a $11.00 target price (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Morgan Stanley boosted their price objective on shares of Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a report on Wednesday, May 27th. Needham & Company LLC set a $11.00 target price on Biohaven in a research note on Monday, June 29th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.75.

Biohaven Stock Performance

Shares of BHVN opened at $13.57 on Friday. The business’s fifty day moving average price is $14.54 and its 200 day moving average price is $11.73. Biohaven has a 12-month low of $7.48 and a 12-month high of $18.57. The stock has a market capitalization of $2.05 billion, a PE ratio of -2.92 and a beta of 1.26. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15).

Hedge Funds Weigh In On Biohaven

Several institutional investors have recently modified their holdings of the company. AQR Capital Management LLC grew its position in shares of Biohaven by 49.4% during the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock worth $2,761,000 after acquiring an additional 37,981 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Biohaven by 32.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after purchasing an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Biohaven by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after purchasing an additional 41,040 shares during the period. Intech Investment Management LLC boosted its stake in Biohaven by 80.3% during the 1st quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after purchasing an additional 27,433 shares during the period. Finally, Quantbot Technologies LP boosted its stake in Biohaven by 1,097.8% during the 2nd quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock valued at $125,000 after purchasing an additional 8,102 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.